Phase I trial of α-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer
- 31 December 1986
- Vol. 28 (6), 508-511
- https://doi.org/10.1016/0090-4295(86)90154-8
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancerCancer, 1984
- Sequential inhibition of polyamine synthesisCancer Chemotherapy and Pharmacology, 1983
- Antigrowth Effect of Some Inhibitors of Polyamine Synthesis on Transplantable Prostate CancerOncology, 1983
- Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithineThe Prostate, 1982
- Synergistic action of two polyamine antimetabolites leads to a rapid therapeutic response in childhood leukemiaInternational Journal of Cancer, 1981
- Effectiveness of methyl-GAG (methylglyoxal-bis[guanylhydrazone]) in patients with advanced malignant lymphomaBlood, 1981
- The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancerCancer, 1980
- A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum IICancer, 1979
- Anti-proliferative properties of DL-α-difluoromethyl ornithine in cultured cells. A consequence of the irreversible inhibition of ornithine decarboxylaseBiochemical and Biophysical Research Communications, 1978
- Urinary Polyamine Levels in the Diagnosis of Carcinoma of the ProstateJournal of Urology, 1975